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ness research, is on the cusp of a golden era of access to digitized real-
world data, catalyzed by the adoption of electronic health records and the
integration of clinical and biological information with other data. This era
promises more robust insights into what works in health care. Several
barriers, however, will need to be addressed if the full potential of these
new data are fully realized; these will involve both policy solutions and
stakeholder cooperation. Although a number of these issues have been
widely discussed, we focus on the one we believe is the most important
—the facilitation of greater openness among public and private stake-
holders to collaboration, connecting information and data sharing, with
the goal of making robust and complete data accessible to all researchers.
In this way, we can better understand the consequences of health careee front matter Copyright & 2015, International S
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ndence to: Marc L. Berger, Pﬁzer, Real World Datadelivery, improve the effectiveness and efﬁciency of health care systems,
and develop advancements in health technologies. Early real-world data
initiatives illustrate both potential and the need for future progress, as
well as the essential role of collaboration and data sharing. Health
policies critical to progress will include those that promote open source
data standards, expand access to the data, increase data capture and
connectivity, and facilitate communication of ﬁndings.
Keywords: big data, data access, health research, health policy, real-
world data.
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Health research, including health outcomes and comparative
effectiveness research, is on the cusp of a golden era of access
to digitized real-world data that promises to transform the way in
which we understand and practice medicine. Part of this trans-
formation will be driven by the quantity of real-world data that
will be generated—as well as the broader interest in “Big Data.”
Real-world data are collected outside of a clinical trial and used
for health care decision making [1]. Real-world data can include
electronic medical records originating from health care providers,
data used to coordinate and pay for care, and pharmacy data
used to ﬁll prescriptions. Data may also be collected in patient
registries or pragmatic clinical trials. Internet searches and social
media are also a growing source. Real-world data become “big
data” when multiple data sets are combined. Deﬁnitions of big
data can vary, but for this context, the term can be deﬁned by
“high-volume, high velocity and high-variety information assets
that demand cost-effective, innovative forms of information
processing for enhanced insight and decision making” [2]. Thebig data paradigm has been driven by widespread efforts to
digitize and synthesize existing data sources (e.g., electronic
health records [EHRs]) as well as novel mechanisms to capture
both clinical and biological data (e.g., wearable health devices).
Whether small and “real world” or “big,” these new data sources
hold great promise to help improve our ability to develop new
treatments and cures, to predict which ones are most effective,
for which patients, and at what cost. For example, new types of
real-world data could allow researchers to readily identify
target populations of interest, and to identify patients who may
be more likely to respond to treatment. In addition, these data
could signiﬁcantly improve health care delivery by enabling the
development of a learning health care system that provides more
rapid feedback to providers and patients to allow them to
optimize treatment. They could allow health plans to develop
beneﬁts that are tailored to the patient and value based, varying
cost sharing and access on the basis of clinical need. These new
data will certainly have an impact on how we monitor both the
safety and the effectiveness of treatment, and these efﬁciencies
will likely accelerate efforts to replace the current, volume-basedociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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efﬁcient spend of health care dollars.Real-World Data Trends in Health Care
Currently, there are multiple public and private efforts to digitize
and aggregate health information from administrative claims,
EHR, and laboratory tests. Some of these efforts are also collect-
ing additional sources of data including genomic data, patient-
reported data, and biometric data from sensors. Although com-
bining data across sites of care and broadening access has
potential value for health research, it poses a risk to privacy.
Even with the protections provided through the Health Insurance
Portability and Accountability Act [3], there is still the risk of
reidentiﬁcation, particularly if data sets are merged with other
information such as voter registration. Removing personal iden-
tiﬁers, aggregating small samples as required through the Safe
Harbor and Limited Dataset provisions of Health Insurance
Portability and Accountability Act along with careful consider-
ation of what is available through other public use data sets, may
reduce that risk [4,5]. We contend that there exist or there are
emerging solutions that would permit the “mashing” together of
data sets at a patient level with limited risk to privacy and that
the more difﬁcult issue is that of data ownership and access.Patient Ownership and Access of Data
Although some governments are making efforts to permit patients
and researchers greater access to data, most of the health-related
data are aggregated and curated by private companies. In most
cases, charging for access to the data is integral to their business
plans. In many cases, the data have been transformed in some
fashion by the company collecting the data, and therefore it
considers the data as intellectual property. Access may also be
restricted to governmental-sponsored data sets. Some have argued
that one way to reduce access limitations is to give patients
broader rights to control the use of their own data. When patients
have access to their health data, 91% of the time they are willing to
share that data to beneﬁt research [6]. Thus, ready access to data
may be facilitated by the advocacy of patients.
Patients are sharing health information with one another. A
pioneer in promoting the involvement of “citizen scientists” has
been PatientsLikeMe. By allowing patients to publicly track health
indicators, real-world data can be aggregated and analyzed in an
effort to determine their best course of treatment. When an open-
label study with 44 patients suggesting lithium could delay the
onset of amyotrophic lateral sclerosis was published in 2008 [7],
hundreds of patients in the PatientsLikeMe community began to
use lithium, self-tracking symptoms and progression. Patient-
sLikeMe was able to use this data to publish ﬁndings in a major
scientiﬁc journal, showing that lithium did not slow amyotrophic
lateral sclerosis [8]. Although randomized trials were ongoing to
attempt to replicate the original study, PatientsLikeMe was able
to publish preliminary ﬁndings from data provided by these
“citizen scientists” in only 9 months and at a very low cost.
Health care providers have been granted billions of dollars in
incentives to support the implementation of EHRs through the
Health Information Technology for Economic and Clinical Health
Act, part of the American Recovery and Reinvestment Act of 2009.
Receiving those incentives under Health Information Technology
for Economic and Clinical Health Act requires providers to
demonstrate Meaningful Use—a set of standards meant to ensure
that EHRs bring an impact in improving the delivery of care,
improving patient empowerment, and sharing information.
Included in Meaningful Use is the expectation that patients willhave electronic access to their health information, and the tools
to make use of that data; some have characterized this develop-
ment as an important step toward “data liberation.”
One example of data liberation was launched in 2010 by the
Departments of Veterans Affairs and Health & Human Services.
Called the Blue Button initiative, it provides electronic access for
Veterans and Medicare beneﬁciaries to their clinical data. By May
2012, more than 500,000 veterans had accessed their data via the
Blue Button initiative and many data holders in the private sector
have begun to adopt the platform.
Another move toward data liberation is the ongoing initiatives
in 16 states to develop all payer claims databases, which will
aggregate and collect medical, pharmacy, and dental claims data
from plans including Medicaid, Health Insurance Exchange,
Medicare, hospitals, and other sources to facilitate analyses by
qualiﬁed researchers. States vary in their data access policies and
the level of transparency on the research being conducted.
Massachusetts, with a high degree of transparency and access
for qualiﬁed researchers, grants access to deidentiﬁed data for
research under a data use agreement. The process allows for
public comment and includes representatives from a broad range
of public and private stakeholders in the data release committee.
Private organizations and academics have submitted applications
for more than 20 studies in 2012-2013.
In contrast, the Centers for Medicare & Medicaid Services
tightly manage and limit access to the national, high-quality,
standardized data sets of the U.S. Medicare population. There is
speciﬁcally a ban on commercial organizations using the data,
which limits access to the companies that develop medicines.
This represents a barrier to the data being leveraged to advance
the scientiﬁc understanding of a disease for the targeting of
potential new therapies and their optimal integration into health
care practice. Although it is appropriate to restrict the use of this
data to legitimate research designed to enhance the effectiveness
of the health care system, current restrictions may distort the
pool of potential researchers, the types of research that might be
conducted, and, potentially, the conclusions that could be legit-
imately drawn from that research. One potential policy solution
is to lift the ban on the commercial use of Medicare data, allowing
all researchers who can maintain data privacy within speciﬁed
parameters and use it appropriately for research. This could
stimulate an enormous amount of understanding to optimize
health care delivery for a sizeable and growing part of the
American health care system.Ability to Communicate Research
However, even if data are made available, there may still be
restrictions on how the ﬁndings from analyses are communi-
cated. The Food, Drug and Cosmetic Act’s standard for drug
approval is that the manufacturer demonstrate by “substantial
evidence” that the drug is safe and effective for its intended use,
which generally is understood to mean data from at least two
“adequate and well-controlled” clinical trials. Food and Drug
Administration (FDA) regulations and enforcement practices have
extended the limited statutory reach of the “substantial evidence”
standard beyond the context of a drug’s approval to apply to a
drug’s promotion. FDA deems safety or efﬁcacy claims made by
manufacturers in their advertising or promotional efforts that are
not supported by “substantial evidence” to be “false or mislead-
ing” in violation of the Food, Drug and Cosmetic Act.
This restricts drug manufacturers’ ability to disseminate
truthful, nonmisleading information about a drug’s approved
uses to health care providers. For example, credible, meaningful
scientiﬁc information contained in epidemiologic studies, meta-
analyses, or cross-sectional surveys would not satisfy the
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tively, prohibiting only the product’s manufacturer from discus-
sing this data but not restricting other participants in the health
care ﬁeld. This creates an asymmetrical situation in which the
manufacturer is not able to fully participate in open scientiﬁc
discourse about its therapy. This could be addressed if Congress
were to afﬁrm that the Food, Drug and Cosmetic Act’s “substan-
tial evidence” standard is limited to a drug’s approval. Congress
could then consider requiring a more reasonable standard to assess
a manufacturer’s postapproval communications, such as the Fed-
eral Trade Commission’s “competent and reliable scientiﬁc evi-
dence” standard used to assess false and deceptive advertising.
There is precedent for such action because Congress previously
adopted this approach in section 114 of the Food and Drug
Administration Modernization Act as applied to health care eco-
nomic information intended for a knowledgeable payer audience.Value of Public-Private Collaboration and Data
Sharing
Much more will need to be done before the true value of real-
world data in health care can be realized. Patient advocacy may
be part of the solution, but alone will be ultimately unsuccessful
for two reasons. First, there will be enormous implementation
challenges that will require multisector solutions. Second, as long
as business interests are not aligned, enthusiasm by data aggre-
gators will be muted at best and progress will be slow.
One approach can be modeled on existing public-private
consortia that have formed to address key noncompetitive
challenges—such as the FDA Sentinel Initiative and the Obser-
vational Medical Outcomes Partnership (OMOP) to make progress
on pharmacovigilence methodology. The experience of the OMOP
is illustrative. Launched in 2007, this FDA-led public-private
partnership focused on drug safety and obtained access to 10
large real-world data sources including medical claims and EHR.
These data were deidentiﬁed and uploaded into a cloud environ-
ment. Here, the data could be interrogated within a standardized
framework by a distributed network of researchers. The OMOP
established a common data model, standardized vocabularies to
code information, and standardized health outcome deﬁnitions.
Open source tools and standardized queries were also created.
The OMOP examined challenges to the validity of results from
observational studies, a concern for both researchers and deci-
sion makers, and underlying ongoing controversy regarding the
utility of real-world data studies in decision making. Currently,
scholarly medical journals feature these studies, often with
limited exploration of challenges to their validity. Thus, decision
makers commonly rely on peer-review and researchers’ reputa-
tion because the ad-hoc nature of exploring bias typically eludes
meaningful evaluation. The OMOP has examined thousands of
epidemiologic designs for hundreds of drug-adverse outcome
pairs; this has enabled it to more fully characterize bias and
conﬁdence interval coverage and has shed light on the ability of
these designs to discriminate between positive and negative
controls [9]. The OMOP has begun developing data-driven
approaches to reduce bias and provide more accurate assessment
of the robustness of associations (e.g., 95% conﬁdence intervals
that contain the true effect size 95% of the time) [10]. These
results suggest that it may be possible to obtain more reliable
information from real-world data studies, thereby increasing
acceptance by decision makers.
Another approach is to embed health research into health
care delivery as illustrated by the Salford Lung Study [11,12]. This
study is evaluating Relovair in 4000 patients with chronic
obstructive pulmonary disease and 5000 patients with asthma
in the city of Salford, England, where the eHealth infrastructureincludes a single EHR used by both primary and secondary care.
Sourcing all data from the EHR, the trial will follow patients for 1
year to monitor symptoms, exacerbations, adverse events, con-
tacts with health care providers, and use of other therapies for
symptom control. This collaboration brings together an excep-
tional mix of partners—pharmaceutical, health care authority,
university, hospital administration, local general practitioners,
and community pharmacists. Although the investment required
for establishing the infrastructure for this project was substantial,
it is likely that costs for similar projects in the future will fall
dramatically as progress is made in the interoperability of health
information technology and as new models of integrated delivery
systems emerge.Genomics, Sharing, and Collaboration
Sharing genomics data alongside the EHR produces a number of
unique challenges, technical and social/ethical. The technical
challenges center on the volume of data and are being met by
technical improvements in data compression [13] and search
technologies through initiatives such as Google Genomics [14].
The regulatory frameworks to address the social/ethical chal-
lenges are emerging through international efforts such as the
Global Alliance for Genomics and Health, a coalition of more than
140 member organizations working to enable effective and
responsible data sharing [15].Conclusions
The world is changing for health research. Not everyone is ready
for it. The era of digitized real-world data holds great promise in
its ability to transform health care. Yet this promise can be fully
realized only if access to data is broadened, if connectivity
between data sets is improved, if the methods for analyzing
large data sets are advanced, communication of evidence is
encouraged and put in the right context, and if there are clear
standards for how privacy can be maintained that also recognize
that no solution is entirely secure.
A recent white paper by the 21st Century Cures initiative
observed that the FDA’s review of supplemental applications for
new uses or changes to a product are governed by pathways
established when computers could not identify trends in stat-
istical or clinical data anywhere close to the degree they can
today, let alone what they will be capable of doing tomorrow.
Considering these ongoing developments, should we be rethink-
ing the supplemental approval processes and how real world
data can be leveraged [16]? Isn’t it our collective duty to explore
and rethink how we evaluate and develop medicines, talk about
them, and assess health outcomes in an era of data? Don’t we
owe that to patients?Acknowledgments
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